Overview of Ben-A

Quick Facts about Ben-A

Property	Description
Active ingredient	Albendazole
Form	Tablet, chewable tablet, oral suspension
Pharmacological class	Anthelmintic (Anti-parasitic agent)
General purpose	Eradication of parasitic infections
Origin	Synthetic (Benzimidazole derivative)

What Type of Medicine is Ben-A? (Identity and Classification)

Ben-A is a synthetic pharmaceutical preparation whose active substance is Albendazole, which is chemically defined as a Benzimidazole carbamate derivative. It is fundamentally classified as a broad-spectrum anthelmintic, a high-level category of anti-parasitic agents used to eliminate parasitic organisms from the body. This classification is widely accepted, with Albendazole recognized for treating various parasitic infections in both humans and animals.

Albendazole: What is the General Purpose of this Anti-Parasitic Agent? (Purpose and General Benefit)

The general purpose of the Albendazole in Ben-A is to eradicate parasitic organisms by systemically interfering with their core cellular functions, acting as a larvicidal, ovicidal, and vermicidal agent. The drug is considered a prodrug because it is metabolized in the body into the active compound, Albendazole sulfoxide, which performs the primary therapeutic physiological action. This mechanism, based on microtubule disruption and subsequent energy depletion, ensures the drug’s effectiveness in clearing the parasitic burden associated with various helminthiasis and protozoal infections in mammalian hosts.

What Forms is Ben-A Available In? (Differentiating Features)

Ben-A is available in several pharmaceutical preparations for oral administration. These dosage forms typically include the solid tablet and chewable tablet forms, as well as an oral suspension. The availability of the chewable tablet and oral suspension forms is a key differentiating feature for this preparation, ensuring flexible delivery for patient groups, such as those who may require an alternative to swallowing a conventional solid tablet.

Regulatory References

What side effects are possible with Ben-A?

Possible Side Effects and Safety Information

The safety profile of Ben-A, which contains Albendazole, is officially classified by regulatory authorities based on the frequency and nature of observed adverse reactions. The most commonly documented reactions generally involve the central nervous system and the digestive tract, and include headache, dizziness, abdominal pain, nausea, and vomiting. Transient, reversible elevations in liver enzymes are also classified as common findings.

Organ System Safety and Serious Reactions

The regulatory safety documents formally classify adverse reactions by System-Organ Class (SOC), highlighting risks primarily associated with the Hepatobiliary Disorders and Blood and Lymphatic System Disorders. Serious adverse reactions, though rare, are documented and include hepatotoxicity (such as acute liver failure), and forms of bone marrow suppression (including pancytopenia and aplastic anemia).

Time-Related Patterns and Safety Constraints

Official labels note that some effects may be time-related. For instance, neurological symptoms like seizures in patients being treated for neurocysticercosis may appear soon after treatment begins due to the anti-parasitic action. Because of the risk of serious hematologic and hepatic effects, the safety profile mandates the scheduled monitoring of blood counts and liver enzymes throughout the treatment period. Furthermore, the drug is associated with potential fetal harm, leading to specific safety constraints for females of reproductive potential, and caution is advised in patients with pre-existing hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ben-A emphasizes the absolute mandate to seek immediate professional medical assistance in any suspected ingestion of excessive amounts. Regulators instruct individuals to contact a Poison Control Center right away.

Immediate emergency services should be called if the individual collapses, has a seizure, or experiences difficulty breathing.

Element	Official Regulatory Statement
Documented Manifestations	Severe exposure is associated with pancytopenia (severe reduction in blood cell counts), elevated hepatic enzymes (transaminases), and alopecia (hair loss).
Systems Affected	Hematological system (bone marrow suppression) and Hepatic system (acute liver injury risk).
Antidote Status	No specific antidote is known for Ben-A overdose.

The potential for severe, life-threatening hematological and hepatic outcomes necessitates urgent hospital monitoring. Management is strictly symptomatic and supportive treatment, focusing on addressing the documented toxic manifestations. This may include initial procedures such as gastrointestinal decontamination. Continuous monitoring of peripheral blood cell counts and liver enzymes is required to track and manage the established risks of blood and liver injury.

Therapeutic Uses of Ben-A

What Ben-A Treats: Main Uses and Benefits

Ben-A is commonly used to help manage the presence of parasitic organisms and offers supportive benefit across various conditions. The medication is generally applied in addressing serious conditions like neurocysticercosis and cystic hydatid disease, as well as common intestinal infestations such as ascariasis, hookworm, pinworm, and whipworm.

Therapeutic Scope and Supportive Benefits

The medication offers supportive benefit by addressing the systemic parasitic burden, which is relevant for managing symptoms related to active lesions in the brain and viscera. This assists with maintaining functional stability and contributes to easing the overall symptom load. For patients with opportunistic infections, this therapy supports general well-being by assisting with the management of challenging systemic manifestations.

Quick Fact: Supportive Management of Parasite-Driven Symptoms

Therapeutic Domain	Symptom Axis Addressed	Supportive Benefit
Systemic & Neurological	Symptoms of increased neurological or muscular activity	Helps maintain a sense of stability when symptoms are more noticeable
Gastrointestinal	Symptoms related to inflammatory or irritative states	May assist with maintaining functional stability
Public Health	Conditions marked by increased physiological stress	Contributes to improved day-to-day comfort during symptomatic periods

Regulatory References

DailyMed / NIH Official Albendazole Label

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ben-A (Albendazole)

This section outlines the official population eligibility and non-eligibility rules for Ben-A (Albendazole) as stated in government-approved regulatory documents.

Eligibility Scope

Category	Official Regulatory Status
Populations for Whom Use is Allowed	Adults and children older than 2 years for most infections. Older adults typically require no dose adjustment, but caution is advised with underlying liver conditions.
Populations for Whom Use is Contraindicated	Patients with known hypersensitivity to albendazole or other benzimidazole class compounds. Pregnant women or those suspected of being pregnant.
Age-Related Eligibility Rules	Not recommended in children under 1 year due to insufficient data. The tablet form is generally inappropriate for children under 6 years due to swallowing risk.
Condition-Specific Eligibility Rules	Patients with liver dysfunction require close monitoring of blood counts and liver enzymes during treatment. Renal impairment generally does not require dose adaptation.
Eligibility-Related Restrictions	Females of reproductive potential must use effective contraception during and for a specified period after therapy. Pregnancy testing is a regulatory requirement before initiation.

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines who may be treated by establishing absolute contraindications based on hypersensitivity and pregnancy status. Eligibility is further constrained by labeled requirements for specific populations, such as mandatory monitoring for liver function and the necessity of effective contraception for females of childbearing potential.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ben-A (Albendazole) is primarily defined by its effects on liver metabolism and specific administration conditions, as outlined in official regulatory documents. This information focuses on changes to the active metabolite, Albendazole sulfoxide, systemic exposure.

Pharmacokinetic Interactions

Co-administration with enzyme-inducing agents, such as certain anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine), is documented to reduce the plasma concentration and systemic exposure of Albendazole sulfoxide. Conversely, substances that increase exposure include the anti-parasitic agent praziquantel and the corticosteroid dexamethasone, both of which are reported to increase the active metabolite's systemic levels (AUC/Cmax).

Pharmacodynamic and Substance Interactions

There is a documented risk of additive myelosuppression when Ben-A is co-administered with other myelosuppressive agents. The drug itself induces cytochrome P450 1A, which mandates the monitoring of theophylline plasma concentrations during and after Ben-A treatment. For gastrointestinal absorption, official prescribing information mandates administration with a fatty meal for significantly enhanced oral absorption and to ensure therapeutic systemic levels. The interaction profile notes that hepatic impairment is a population-specific consideration that may significantly affect the drug's pharmacokinetics and increase the risk for related toxicity.

Mechanism of Action

Ben-A's mechanism is defined by the high-affinity binding of its active metabolite, Albendazole sulfoxide, to the parasite's mathbfbeta-tubulin subunit, the core protein of the cytoskeleton. This interaction acts as a potent inhibitor of tubulin polymerization, causing the immediate collapse of the structural framework necessary for the integrity and function of the parasite's cells.

The resulting structural damage to the cellular machinery and surface tissues prevents the essential uptake of glucose from the host. This interruption of the glucose utilization pathway rapidly depletes the parasite's glycogen reserves, leading to a profound deficit in ATP (energy). This cascade of energy starvation is the key physiological consequence that results in the complete immobilization and subsequent destruction of the organism.

The activity of this microtubule-targeting mechanism is constrained by the parasite's metabolic state. The mechanistic effect is most pronounced in actively metabolizing organisms but may be physiologically limited by forms that are structurally protected or metabolically quiescent, such as old, calcified cysts. In such cases, the mechanism may function primarily to suppress cell division rather than cause rapid organism destruction.

Dosage and Administration Information

Ben-A (Albendazole) is administered orally and is available in forms such as tablets, chewable tablets, and oral suspension. The proper administration of the medicine is highly dependent on achieving adequate systemic absorption, a requirement that directs the intake conditions. Standard administration protocols specify that the medicine must be taken with a meal, ideally one containing fat, as this significantly increases the amount of drug absorbed by the body. The tablets may be crushed or chewed and swallowed with water if the patient has difficulty swallowing the whole pill, providing flexibility in delivery.

The standard dosing regimen for systemic conditions like cystic hydatid disease and neurocysticercosis is twice daily (BID). The exact dose is determined by body weight: patients weighing 60 kg or more typically receive 400 mg BID, while those under 60 kg receive a weight-based dose of 15 mg/kg/day in divided doses, not to exceed 800 mg daily. Dosage adjustment is not expected for renal impairment, but patients with hepatic impairment require careful evaluation due to potential increases in systemic exposure.

The duration of use varies based on the parasitic condition. Treatment for cystic hydatid disease follows a structured cyclic regimen consisting of 28 consecutive days of dosing followed by a 14-day drug-free interval, repeated for a total of three cycles. For neurocysticercosis, a shorter, continuous course is prescribed, typically ranging from 8 to 30 days. The protocol for neurocysticercosis also includes the procedural requirement for co-administration with corticosteroids to manage inflammatory responses.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has investigated whether treatment is associated with changes in clinical outcomes in patients with Chronic Myeloid Leukemia (CML).

Studies explored the drug as a monotherapy and in combination with other agents. Most trials focused on treatment-naïve adult patients with confirmed CML.

A Phase III clinical trial reported reduction of disease markers over a 5-year period. In this study, 80% of participants achieved a major molecular response (MMR) after 12 months.

Combination Therapy Research

Studies have examined the use of the drug in combination with other treatments.

Interferon-Alpha: Several smaller studies evaluated whether the combination with interferon-alpha is associated with changes in pain associated with splenomegaly. Findings across these small trials were mixed.
Chemotherapy Agents: Research has explored the combination with low-dose cytarabine, primarily in the context of advanced or accelerated phase CML.

Adverse Events and Tolerability Data

The frequency and nature of adverse events associated with the medication were recorded in two large-scale clinical trials.

Studies also reported that participants taking the medication experienced minor gastrointestinal side effects, including nausea and mild diarrhea, which were often observed to decrease after the first month of treatment.

In clinical trials, researchers conducted close monitoring of liver enzymes upon initiation of therapy.

Findings on Symptom Management

The formulation was evaluated regarding its association with changes in constitutional symptoms, such as fever, night sweats, and fatigue.

Limitations of Current Evidence

Research evaluated whether the drug is associated with a 45% difference in the risk of disease progression. These results are limited to the specific population and duration of the study.

Currently, it is not yet clear whether the long-term safety profile beyond 5 years of continuous use has been fully established.

Studies excluded participants with pre-existing heart conditions.

Frequently Asked Questions (FAQ)

Common questions about Ben-A (FAQ)

Q: What happens if a dose of Ben-A is missed?

A: The official recommendation is that if a dose is missed, the medicine is generally taken with food as soon as it is recalled. However, if the time is near the next scheduled dose, the prescribed guidance is to typically skip the missed dose and return to the regular schedule. Taking two doses at the same time is not recommended based on regulatory information.

Q: Can I take Ben-A with common pain relievers like ibuprofen?

A: Official regulatory documents emphasize the importance of informing a healthcare provider about all medications they are currently taking before starting Ben-A. This disclosure includes prescription, nonprescription (over-the-counter) medicines, and common pain relievers, allowing for the proper evaluation of potential drug interactions.

Q: Is Ben-A known to interact with herbal supplements?

A: Official prescribing information advises informing a healthcare provider about all products being taken, including herbal supplements and vitamins. This allows for a complete assessment of the risk of interactions, which can affect how Ben-A works.

Q: Does alcohol interact with Ben-A?

A: While the official regulatory documents do not list a specific, formal interaction between Ben-A and alcohol, general advice for patients taking this medicine is to consult with their healthcare provider about alcohol consumption. They can provide guidance based on individual health status and the treatment plan.

Q: What does the term 'contraindication' mean for Ben-A?

A: A contraindication is a condition or factor that serves as a reason to withhold a medical treatment due to the potential for harm. For Ben-A, official regulatory documents list specific contraindications, which include having a known allergy or hypersensitivity to the medicine, as well as being pregnant or suspected of being pregnant.

Q: What should I do if I experience a side effect listed in the official documents?

A: Official counseling materials state that a person is expected to contact their healthcare provider immediately or seek emergency medical help if signs of a serious problem are experienced. Examples of serious concerns include a severe, persistent headache, vision changes, or signs of a severe allergic reaction.

Q: Is Ben-A an addictive medicine?

A: Ben-A (Albendazole) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies. This indicates that the medicine is not considered to have potential for abuse or addiction.

Q: Is Ben-A available over the counter in any country?

A: In the United States, Ben-A (Albendazole) is strictly a prescription-only medicine. Its status as a prescription-only medicine is related to the regulatory requirement for professional medical supervision, including necessary laboratory monitoring and assessment of potential safety risks.

Q: Does Ben-A affect sleep patterns?

A: The official safety profile for Ben-A lists potential effects on the nervous system, such as headache and dizziness. While sleep patterns are not directly listed, nervous system effects can sometimes influence rest. If a person has concerns about changes to their sleep while taking the medicine, consultation with a healthcare provider is generally recommended.

Q: Are there any known interactions between Ben-A and birth control pills?

A: Yes, the official regulatory profile establishes a specific requirement regarding contraception for females of reproductive potential. Because of the risk of potential harm to a fetus, the requirement is established that effective methods of birth control are used during treatment and for a specified period following therapy.

Q: Is it true that Ben-A needs to be taken at the same time every day?

A: Yes, patient information recommends taking Ben-A at the same time or times each day. This practice helps to maintain consistent blood levels of the active metabolite, Albendazole sulfoxide, which supports the medicine's effectiveness throughout a prescribed treatment cycle.

Q: How long does Ben-A stay in your system after the last dose?

A: The time it takes for a medicine to be cleared from the body is often measured by its half-life. The active compound of Ben-A, Albendazole sulfoxide, has a reported mean apparent terminal elimination half-life that typically ranges from 8 to 12 hours.

Q: What are the official guidelines about driving while taking Ben-A?

A: Official regulatory information in some regions, such as the European Summary of Product Characteristics, states that Ben-A is not expected to interfere with a person’s ability to drive or operate machinery. If a person experiences side effects like dizziness or fatigue, caution is generally advised.

Q: Why is Ben-A only available by prescription?

A: Ben-A is restricted to prescription-only status. This prescription status is based on regulatory considerations that include the need for professional medical oversight and mandatory regular monitoring of liver enzymes and blood counts due to potential serious effects.

Q: Is there a generic version of Ben-A available?

A: Yes, a generic version of the active ingredient, Albendazole, is generally available. Generic medicines contain the same active ingredient and are required to meet the same quality and effectiveness standards as the original brand-name product.

Q: What are the official recommendations regarding breastfeeding while taking Ben-A?

A: Regulatory information indicates that the active substance and its metabolite are minimally excreted into breast milk. While some official guidance contains cautionary information, organizations like the World Health Organization (WHO) have stated that a single oral dose may be given to women who are breastfeeding.

How should Ben-A be stored and disposed of?

How to Store and Dispose of Ben-A?

Ben-A (Albendazole) must be stored at controlled room temperature, specifically between mathbf20 C and mathbf25 C (mathbf68 F and mathbf77 F), with excursions permitted up to 30 C.

Storage Conditions

Requirement	Details
Temperature & Protection	Do not freeze. Keep in a dry place, protected from excess heat and moisture.
Container & Integrity	Store in the original container and keep the cap tightly closed.
Child Safety	Mandatory requirement to keep the medicine out of the reach and sight of children.

Disposal Instructions

Official disposal guidance recommends discarding unused or expired Ben-A through a drug take-back program. The product must not be thrown away via the sink, toilet, or standard household wastewater. If a take-back option is unavailable, the medicine should be mixed with an unpalatable substance and placed in a sealed container before disposal in household trash.

Ben-A